TG Therapeutics Inc
XNAS:TGTX
| Market Cap (Intraday) | 7.58B |
| Current PE | 16.41 |
| Forward PE | 35.88 |
| 2yr Forward PE | 19.57 |
| 10-Day MA | $41.40 |
| 50-Day MA | $36.21 |
| 200-Day MA | $32.48 |
TG Therapeutics Inc Stock, XNAS:TGTX
3020 Carrington Mill Boulevard, Suite 475, Morrisville, North Carolina 27560
United States of America
Phone: +1.212.554.4484
Number of Employees: 338
Description
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.